Post-hoc analysis shows promising results in reducing functional vision loss with avacincaptad pegol
Findings from a post-hoc analysis from the GATHER trials presented at ARVO 2023 signaled that reduced rate of vision loss was correlated with reduced geographic atrophy (GA) growth in patients receiving avacincaptad pegol (ACP). These findings suggest that ACP may be a promising treatment option for patients with GA, regardless of their baseline patient and lesion characteristics.
In an accompanying press release, Carl Danzig, MD, Director, Vitreo-Retinal Services, Rand Eye Institute, Deerfield Beach, Florida, who presented the findings at ARVO said:
“This is the first time a relationship between disease progression and worsening visual acuity has been observed in GA, connecting anatomy and function. These data suggest that in the ACP-treated group, the reduction in growth of GA resulted in an overall lower rate of vision loss.”
The GATHER2 study was a Phase 3 trial that investigated the safety and efficacy of ACP 2 mg in treating geographic atrophy (GA) in eyes that met certain criteria. The study involved monthly intravitreal injections of ACP 2 mg or a sham treatment for 12 months, with the primary analysis measuring the mean rate of growth based on GA area. A subgroup analysis was also performed to explore the consistency of treatment response based on baseline patient and lesion characteristics.
The study involved 447 patients who were randomized to receive either ACP 2 mg or a placebo. The primary objective of the study was met at 12 months, with a statistically significant reduction in the mean rate of GA growth in patients treated with ACP 2 mg. The treatment was consistently more effective than the placebo in subgroups of patients. The differences in treatment efficacy ranged from 0.031 mm to 0.085 mm.
Reference
Danzig CJ, et al. Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study. Presented at: ARVO 2023.
This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.
